

Oriana Ciani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4122773/publications.pdf>

Version: 2024-02-01

91
papers

2,161
citations

201674

27
h-index

254184

43
g-index

95
all docs

95
docs citations

95
times ranked

2987
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Exercise Rehabilitation on Exercise Capacity and Quality-of-Life in Heart Failure. Journal of the American College of Cardiology, 2019, 73, 1430-1443.	2.8	172
2	Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials. European Journal of Heart Failure, 2018, 20, 1735-1743.	7.1	125
3	Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. BMJ, The, 2013, 346, f457-f457.	6.0	119
4	Determinants of demand for total hip and knee arthroplasty: a systematic literature review. BMC Health Services Research, 2012, 12, 225.	2.2	114
5	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. Value in Health, 2017, 20, 487-495.	0.3	101
6	An Economic Perspective on Urinary Tract Infection: The "Costs of Resignation". Clinical Drug Investigation, 2013, 33, 255-261.	2.2	69
7	VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS. International Journal of Technology Assessment in Health Care, 2014, 30, 312-324.	0.5	69
8	Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget, 2016, 7, 72343-72355.	1.8	57
9	Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study. BMJ Open, 2016, 6, e009669.	1.9	53
10	HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES: A SURVEY OF NON-EUROPEAN UNION AGENCIES. International Journal of Technology Assessment in Health Care, 2015, 31, 154-165.	0.5	49
11	A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourology and Urodynamics, 2017, 36, 1178-1186.	1.5	49
12	Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.. Health Technology Assessment, 2012, 16, iii-iv, 1-277.	2.8	49
13	Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. Journal of Clinical Epidemiology, 2015, 68, 833-842.	5.0	48
14	Validation of Exercise Capacity as a Surrogate Endpoint in Exercise-Based Rehabilitation for Heart Failure. JACC: Heart Failure, 2018, 6, 596-604.	4.1	47
15	Response to COVID-19: was Italy (un)prepared?. Health Economics, Policy and Law, 2022, 17, 1-13.	1.8	46
16	Harnessing Digital Health Technologies During and After the COVID-19 Pandemic: Context Matters. Journal of Medical Internet Research, 2020, 22, e21815.	4.3	45
17	Diffusion and use of health technology assessment in policy making: What lessons for decentralised healthcare systems?. Health Policy, 2012, 108, 194-202.	3.0	39
18	The role of health technology assessment bodies in shaping drug development. Drug Design, Development and Therapy, 2014, 8, 2273.	4.3	39

#	ARTICLE	IF	CITATIONS
19	De innovatione: The concept of innovation for medical technologies and its implications for healthcare policy-making. <i>Health Policy and Technology</i> , 2016, 5, 47-64.	2.5	38
20	Linking the Regulatory and Reimbursement Processes for Medical Devices: The Need for Integrated Assessments. <i>Health Economics (United Kingdom)</i> , 2017, 26, 13-29.	1.7	37
21	Mudâ€Bath Therapy in Addition to Usual Care in Bilateral Knee Osteoarthritis: An Economic Evaluation Alongside a Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2017, 69, 966-972.	3.4	34
22	Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis. <i>Health Technology Assessment</i> , 2019, 23, 1-98.	2.8	34
23	Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines. <i>Pharmacoeconomics</i> , 2020, 38, 1055-1070.	3.3	33
24	Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 516-516.	46.4	32
25	Value Lies in the Eye of the Patients: The Why, What, and How of Patient-reported Outcomes Measures. <i>Clinical Therapeutics</i> , 2020, 42, 25-33.	2.5	32
26	Distinguishing features in the assessment of mHealth apps. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 521-526.	1.4	32
27	Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Value in Health</i> , 2017, 20, 336-344.	0.3	29
28	An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. <i>Social Science and Medicine</i> , 2022, 292, 114519.	3.8	29
29	HEALTH TECHNOLOGY ASSESSMENT METHODS GUIDELINES FOR MEDICAL DEVICES: HOW CAN WE ADDRESS THE GAPS? THE INTERNATIONAL FEDERATION OF MEDICAL AND BIOLOGICAL ENGINEERING PERSPECTIVE. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 276-289.	0.5	28
30	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2021, 181, 1575.	5.1	28
31	A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 95-117.	2.5	27
32	Development features and study characteristics of mobile health apps in the management of chronic conditions: a systematic review of randomised trials. <i>Npj Digital Medicine</i> , 2021, 4, 144.	10.9	24
33	Exercise training for chronic heart failure (ExTraMATCH II): Protocol for an individual participant data meta-analysis. <i>International Journal of Cardiology</i> , 2014, 174, 683-687.	1.7	23
34	Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. <i>BMJ Open</i> , 2019, 9, e025483.	1.9	22
35	A biasâ€adjusted evidence synthesis of RCT and observational data: the case of total hip replacement. <i>Health Economics (United Kingdom)</i> , 2017, 26, 46-69.	1.7	21
36	Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies. <i>Medical Decision Making</i> , 2021, 41, 439-452.	2.4	21

#	ARTICLE	IF	CITATIONS
37	Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies. <i>Health Policy</i> , 2021, 125, 602-608.	3.0	20
38	Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. <i>BMJ, The</i> , 2021, 374, n2191.	6.0	19
39	Measuring Value in Health Care: A Comparative Analysis of Value-based Frameworks. <i>Clinical Therapeutics</i> , 2020, 42, 34-43.	2.5	18
40	Method for Movement and Gesture Assessment (MMGA) in Ergonomics. <i>Lecture Notes in Computer Science</i> , 2009, , 591-598.	1.3	17
41	Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments. <i>Journal of Clinical Epidemiology</i> , 2021, 136, 26-36.	5.0	17
42	Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. <i>BMC Cancer</i> , 2018, 18, 715.	2.6	15
43	Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective. <i>Expert Review of Medical Devices</i> , 2020, 17, 993-1006.	2.8	15
44	European diabetes research and its funding, 2002â€“2013. <i>Diabetic Medicine</i> , 2017, 34, 1354-1360.	2.3	14
45	Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data. <i>Statistics in Medicine</i> , 2020, 39, 1103-1124.	1.6	14
46	Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e62.	0.5	14
47	Broadening the Concept of Value: A Scoping Review on the Option Value of Medical Technologies. <i>Value in Health</i> , 2021, 24, 1045-1058.	0.3	14
48	A scoping review of core outcome sets and their â€“mappingâ€™ onto real-world data using prostate cancer as a case study. <i>BMC Medical Research Methodology</i> , 2020, 20, 41.	3.1	13
49	Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges. <i>European Journal of Health Economics</i> , 2021, 22, 1253-1273.	2.8	13
50	Recommendations for developing a lifecycle, multidimensional assessment framework for mobile medical apps. <i>Health Economics (United Kingdom)</i> , 2022, 31, 73-97.	1.7	13
51	Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapy. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 35.	1.5	11
52	Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study. <i>BMC Medicine</i> , 2018, 16, 45.	5.5	10
53	The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?. <i>Cancer Management and Research</i> , 2021, Volume 13, 8457-8471.	1.9	10
54	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. <i>Frontiers in Public Health</i> , 2020, 8, 612410.	2.7	9

#	ARTICLE	IF	CITATIONS
55	Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence. <i>Health Economics (United Kingdom)</i> , 2022, 31, 44-72.	1.7	9
56	Current and Future Trends in the HTA of Medical Devices. <i>IFMBE Proceedings</i> , 2016, , 1345-1348.	0.3	6
57	The impacts of diabetes research from 31 European Countries in 2002 to 2013. <i>Research Evaluation</i> , 2018, 27, 270-282.	2.6	6
58	The Net Benefit of a treatment should take the correlation between benefits and harms into account. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 148-158.	5.0	6
59	Coverage with evidence development for medical devices in Europe: Can practice meet theory?. <i>Health Economics (United Kingdom)</i> , 2022, 31, 179-194.	1.7	6
60	Pervasive technology in Neonatal Intensive Care Unit: A prototype for newborns unobtrusive monitoring. , 2008, 2008, 1292-5.		5
61	SURROGATE, FRIEND OR FOE? THE NEED FOR CASE STUDIES OF THE USE OF SURROGATE OUTCOMES IN COST-EFFECTIVENESS ANALYSES. <i>Health Economics (United Kingdom)</i> , 2013, 22, 251-252.	1.7	5
62	Mapping research activity on mental health disorders in Europe: study protocol for the Mapping_NCD project. <i>Health Research Policy and Systems</i> , 2016, 14, 39.	2.8	5
63	Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 209-221.	1.4	5
64	Lung cancer stage distribution from before COVID-19 through 18 months of the pandemic: the experience of a large-volume oncological referral centre. <i>European Journal of Surgical Oncology</i> , 2022, 48, 470-471.	1.0	5
65	An Electronic Patient-Reported Outcome Mobile App for Data Collection in Type A Hemophilia: Design and Usability Study. <i>JMIR Formative Research</i> , 2021, 5, e25071.	1.4	5
66	A more evidence based approach to the use of surrogate end points in policy making. <i>BMJ: British Medical Journal</i> , 2011, 343, d6498-d6498.	2.3	3
67	PA2 Hospital-Based HTA in Italy: Diffusion and Potential Impact. <i>Value in Health</i> , 2012, 15, A283.	0.3	3
68	Decision uncertainty and value of further research: a case-study in fenestrated endovascular aneurysm repair for complex abdominal aortic aneurysms. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 15.	1.5	3
69	Exercise training for chronic heart failure (ExTraMATCH II): Why all data are not equal. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1229-1231.	1.8	3
70	Construction of Inflatable Lungs to Simulate Respiratory Motion in Myocardial Perfusion Imaging. <i>IFMBE Proceedings</i> , 2016, , 1337-1341.	0.3	2
71	Validation of surrogate end points for overall survival in advanced colorectal cancer: A harmonized approach is needed. <i>Journal of Clinical Epidemiology</i> , 2016, 70, 277-278.	5.0	2
72	PCV8 - IMPACT OF EXERCISE-BASED REHABILITATION IN PATIENTS WITH HEART FAILURE (EXTRAMATCH II) ON EXERCISE CAPACITY AND HEALTH-RELATED QUALITY OF LIFE: A META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM RANDOMISED TRIALS. <i>Value in Health</i> , 2018, 21, S94.	0.3	2

#	ARTICLE	IF	CITATIONS
73	The evaluation of medical devices: are we getting closer to solve the puzzle? A review of recent trends. IFMBE Proceedings, 2018, , 916-919.	0.3	2
74	Need for better reporting of trials with surrogate endpoints: SPIRIT CONSORT-SURROGATE extensions. Journal of Epidemiology and Community Health, 0, , jech-2022-219294.	3.7	2
75	Validation of Surrogate Endpoints in Advanced Solid Tumours: Systematic Review of Statistical Methods, Results, and Implications for Policy Makers. Value in Health, 2013, 16, A327.	0.3	1
76	Comparing Drug and Nondrug Technologies in Comparative Effectiveness Research. , 2016, , 275-290.		1
77	Introduction to economic evaluation and health technology assessment. , 2020, , 789-794.		1
78	Health technology assessment of medical devices. , 2020, , 795-798.		1
79	Value-based healthcare: Il nuovo approccio di AIFA alla determinazione multidimensionale del valore. Global & Regional Health Technology Assessment, 2020, 7, 9-13.	0.1	1
80	PRM60 General Methodological Issues in Cost-Effectiveness Analysis Inspired by the Assessment of Dasatinib, Nilotinib and Imatinib for 1st- Line Chronic Myeloid Leukaemia. Value in Health, 2012, 15, A471.	0.3	0
81	Comparing Drug and Non-drug Technologies in Comparative Effectiveness Research. , 2015, , 1-17.		0
82	Decision Uncertainty and Need for Further Research: A Case-Study in Fenestrated Endovascular Aneurysm Repair for Complex Abdominal Aortic Aneurysms. Value in Health, 2016, 19, A356-A357.	0.3	0
83	Diffusion of Trans-Arterial Radioembolization for The Treatment of Intermediate-Advanced Hepatocellular Carcinoma in Italy: A Budget Impact Analysis. Value in Health, 2016, 19, A687.	0.3	0
84	Cost-Effectiveness Analysis of A Potential Treatment Introduction for Anorexia-Cachexia in Non-Small Cell Lung Cancer Patients. Value in Health, 2016, 19, A729-A730.	0.3	0
85	PP100 Economic Evaluation Of A New Non-Antibiotic First-line Treatment Of Recurrent Urinary Tract Infections. International Journal of Technology Assessment in Health Care, 2017, 33, 118-119.	0.5	0
86	Results Of Individual Participant Data Meta-Analysis VS Aggregate Data Meta-Analysis Of RCTS Of Exercise Rehabilitation In Chronic Heart Failure. Value in Health, 2017, 20, A767.	0.3	0
87	Non-communicable diseases: mapping research funding organisations, funding mechanisms and research practices in Italy and Germany. Health Research Policy and Systems, 2017, 15, 85.	2.8	0
88	Clinical Core Outcomes Sets in Real World Data. Value in Health, 2018, 21, S112.	0.3	0
89	PNS183 WHAT METHODS ARE APPLIED IN ASSESSING THE CLINICAL AND COST EFFECTIVENESS OF HEALTH TECHNOLOGIES BASED ON THE USE OF SURROGATE OUTCOMES: A COMPARISON OF EVALUATION REPORTS ACROSS INTERNATIONAL HEALTH TECHNOLOGY ASSESSMENT AGENCIES. Value in Health, 2019, 22, S316.	0.3	0
90	Balneotherapy in knee osteoarthritis: a cost/effectiveness analysis alongside an italian randomized controlled clinical trial. Boletín De La Sociedad Española De Hidrología Médica, 2018, 33, 61-62.	0.0	0

#	ARTICLE	IF	CITATIONS
91	The Importance of Using the Appropriate Model for Systematic Reviews and Meta-analysesâ€”Reply. JAMA Internal Medicine, 2022, 182, 357.	5.1	0